Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced a significant development in its partnership with Nestlé Health Science—a non-binding memorandum of understanding whereby Nestlé Health Science will acquire certain tangible and intangible assets related to VOWST (fecal microbiota spores, live-brpk) capsules. This pivotal transaction will grant Nestlé Health Science full control over the development, commercialization, and […]
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The biologics license application (BLA) of the American microbiome therapeutics company for SER-109 has been given a prescription drug user fee act (PDUFA) action […]
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). According to the US-based biotech company, SER-301 is an oral fermented microbiome therapeutic designed for dampening the unusual gastrointestinal inflammation central to ulcerative colitis and promote clinical remission in […]
